Pembrolizumab toxicity
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Pembrolizumab toxicity. Axonal peripheral neuropathy (PN), Myasthenia gravis (MG), Myositis, Necrotic myositis. Fully referenced neurology checklist.
Peripheral neurological features
- Axonal peripheral neuropathy (PN)
- Myasthenia gravis (MG)
- Myositis
- Necrotic myositis
- Polyradiculopathy
- Vasculitic neuropathy
- Miller Fisher syndrome (MFS)
Central neurological features
Locked: subscribe to see this section.
Renal features
Locked: subscribe to see this section.
Dermatological features
Locked: subscribe to see this section.
Ophthalmological features
Locked: subscribe to see this section.
Haematological features
Locked: subscribe to see this section.
Pulmonary features
Locked: subscribe to see this section.
Hepatobiliary features
Locked: subscribe to see this section.
Endocrine features
Locked: subscribe to see this section.
Cardiac features
Locked: subscribe to see this section.
Rheumatological features
Locked: subscribe to see this section.
Gastrointestinal features
Locked: subscribe to see this section.
References
- Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016; 29:806-812.
- Izzedine H, Mateus C, Boutros C, et al. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 2017; 32:936-942.
- Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment. J Immunother 2017; 40:221-223.
- Yen CC, Su HC, Chu CY, et al. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. Lung Cancer 2018; 120:149-151.
- Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017; 82:128-136.
- And 61 more. Subscribe to see the full list
